CAR T-Cell Therapy Saved My Life: Robyn's Non-Hodgkin Lymphoma Story | The Patient Story

Published 2023-04-24
Robyn was diagnosed with Diffuse Large B-Cell Lymphoma. Four years after going through R-CHOP chemotherapy, she relapsed and went through more chemotherapy, a stem cell transplant, and radiation. She relapsed a second time only 9 months after therapy. This time, she joined a clinical trial for CAR T-cell therapy.

In this conversation, Robyn, a three-time DLBCL survivor, and two top lymphoma specialists, Dr. Tycel Phillips from the City of Hope and Dr. Joshua Brody from Mount Sinai, discuss the latest research and treatment options n the most common subtype of non-Hodgkin lymphoma: diffuse large B-cell lymphoma (DLBCL).

Thank you to Genmab and AbbVie for their support of our patient education program.

Full story & transcript → www.thepatientstory.com/medical-experts/dlbcl-roun…

Join Our Community:
Website : www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story

02:06 - What is diffused large B-cell lymphoma.
03:54 - What are the different treatment options for DLBCL?
05:45 - What is the treatment for a patient who relapses in the first 6-12 months?
09:25 - What is CAR T-Cell Therapy?
11:54 - Benefits and challenges of CAR T-Cell Therapy.
13:46 - CAR T-Cell therapy for refractory patients

#cancersurvivor #cancerstories #cancer #thepatientstory #dlbcl #lymsm #nonhodgkinlymphoma #lymphoma #lymphomasurvivor #lymphomaawareness #cancertreatments #cancerresearch

All Comments (3)
  • Had Car t in 2021 had a relapse late 2022, just got singed up for tmCD19-18 which is a new study. Currently scheduled to start treatment in November will let know how I make out.
  • @kittyfarkas
    Thank you for updates. I had benamustine and rituxinab in 2018 for cll. Starting to relapse. I doubt I can do car t as I'm older.